## Gene Summary
CRY1, or Cryptochrome Circadian Regulator 1, is a gene involved in the circadian regulation of the body, which plays a central role in maintaining circadian rhythms that govern sleep-wake cycles, hormone release, and other important bodily functions. CRY1 encodes a protein member of the cryptochrome family, which acts as a repressor that inhibits CLOCK-BMAL1 mediated transcription activation. The expression of this gene is variable across tissue types, but it is predominantly observed in places such as the retina and brain where circadian rhythms are crucial.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CRY1 impacts various physiological processes and is integral to the molecular mechanisms controlling the circadian clock. Dysregulation of CRY1 has been implicated in several disorders, notably mood disorders, metabolic syndromes, and certain types of cancer. It is also associated with sleep disorders such as Delayed Sleep Phase Disorder (DSPD), particularly due to mutations that lengthen the circadian cycle. Regarding pathways, CRY1 interacts significantly with other core circadian clock genes and proteins to regulate transcription through feedback loops in the circadian cycle, influencing numerous downstream effects in gene expression across the body.

## Pharmacogenetics
The pharmacogenetics of CRY1 relates mainly to its influence on the metabolism of certain drugs through its role in regulating circadian rhythms, which can affect the pharmacokinetics of medications administered with respect to time. No specific drugs have been conclusively associated with CRY1-related genetic variations in terms of clinical use guidelines. However, understanding the gene's implications in circadian disorders may prompt considerations for timing in drug administration, enhancing therapeutic efficacy and minimizing side effects. Further research into CRY1 could elucidate more direct links between its polymorphisms and specific pharmacological interventions.